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Objective: This phase I IDE study (STAPLE-1) evaluated the primary endpoints of safety (major device-related adverse
events at 30 days) and feasibility (successful deployment of all endograft components) of the Aptus Endovascular
abdominal aortic aneurysm (AAA) Repair System (Aptus Endosystems, Inc, Sunnyvale, Calif) to treat AAAs.
Methods: A prospective, single arm Federal Drug Administration (FDA) Phase I IDE study was performed. The Aptus
endograft is a three-piece modular device with a flexible unsupported main body and two fully supported limbs in a 5.3
mm outer diameter (OD) (16F) delivery system for all iliac limbs and two of three main body sizes. The largest main body
(29 mm diameter) is in a 6 mm (18 F OD) delivery system. EndoStaples measuring 4 mm (length) by 3 mm (diameter)
designed to provide transmural graft fixation to the adventitia are applied independent of the endograft delivery system.
Inclusion criteria included a proximal aortic neck length of 12 mm and iliac landing zone of 10 mm. Secondary endpoints
included freedom from endoleaks, rupture, migration, and device integrity.
Results: Twenty-one (21) patients were enrolled at five centers. All patients received the Aptus Endograft and EndoStaples.
Ninety-six EndoStaples (range, 2-10; median, 4) were implanted. All patients (n  21) completed 1-month and 6-month
follow-up evaluation and 14 completed 1-year follow-up. Two proximal cuffs and one limb extension were used as adjunctive
endograft components at implantation. Three secondary interventions were performed in 2 patients for limb thrombosis.
There were no EndoStaple-related adverse events, device integrity failures, migrations, or conversions.
Conclusion: These results of the STAPLE-1 trial document the acute safety and feasibility of the Aptus Endograft and
EndoStaples. Early follow-up demonstrates excellent 6-month and 1-year results. A pivotal phase II trial is underway at
25 US centers. ( J Vasc Surg 2009;49:851-8.)The therapy for infrarenal abdominal aortic aneurysm
(AAA) in the United States was transformed in 1999 with
the approval by the Food and Drug Administration (FDA)
of the first two aortic endografts indicated for the treatment
of infrarenal AAA.1,2 Over the ensuing years, the vascular
workforce in the United States has increasingly employed
endovascular techniques to repair AAAs using a variety of
different endograft technologies. Much of the enthusiasm
for endovascular aortic grafting has been driven by the
highly reproducible reductions of acute morbidity and
mortality as well as a very high initial technical success
rate.1,2 The primary impediments to wider endovascular
graft adoption over open surgical reconstruction include
complications related to: (1) the relatively large size of the
catheters required to implant endografts, (2) the significant
increase in secondary interventions required to maintain
the effectiveness of endografts, (3) the diminished reliabil-
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Vascular Surgery.doi:10.1016/j.jvs.2008.10.064ity of the graft attachment to the aorta resulting in neck
dilatation and/or graft migration and late aneurysm rup-
ture, and (4) the requirement for long-term surveillance
with computed tomography (CT) and intravenous (i.v.)
contrast.3-8
This report documents the early results of a multicenter
trial that represents the first human use in the US of a novel
approach to an aortic endograft technique that utilizes a
fixation technique completely independent of the en-
dograft itself. While this fixation technology directly ad-
dresses migration and endograft sealing issues, its true
significance is the freedom it allows for new developments
in endograft design and delivery. It also enables the opera-
tor to determine the degree and location of fixation, essen-
tially analogous to the process of suturing an open surgical
aortic prosthesis.
Device description. The Aptus AAA Endovascular
Repair System (Aptus Endosystems Inc, Sunnyvale, Calif) is
a proprietary aortic endograft system comprised of three
essential components: (1) a bifurcated modular endograft
with two docking limbs, (2) a deflectable sheath specifically
designed for EndoStaple delivery, and (3) an electronically-
controlled EndoStaple applier and helical EndoStaples.
The main body of the graft has a proximal nitinol self-
expanding stent that functions to temporarily fix the en-
dograft in the aorta upon deployment and as a target zone
for proximal staple implantation to complete proximal fix-
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applied across the stented portion of the main body create
a proximal seal and fixation. The remainder of the body is
unsupported polyester material that is designed to accom-
modate cyclic changes of aortic length during the cardiac
cycle and enable the proximal stent to orient to the local
axis of the aortic neck to allow a tension-free proximal
attachment (Fig 1). The unsupported body of the graft is
designed to also allow for compliance in the chronic re-
modeling of the aneurysm sac and aortic morphology. Two
docking limbs are utilized to complete each endograft and
are supplied in 2-cm length increments (Fig 2). All of the
docking limbs are made of polyester supported by a full-
length nitinol self-expanding stent that provides radial sup-
port while still allowing longitudinal flexibility (Fig 3). The
deployment of the docking limbs into themain body results
in a specific locking action between the main body and
docking limbs so that limb distraction requires disruption
of either the fabric or stents as opposed to a simple friction
fit. This results in a functional unibody graft once
Fig 1. The Aptus main body.
Fig 2. The Aptus Endograft main body and two docking limbs.implanted.The fixation of the endograft is achieved by the delivery
of helical staples that measure approximately 3 mm in
diameter by 4 mm in length. These staples are constructed
of a metallic alloy (MP35N LT) which is similar to Elgiloy
(Elgiloy Specialty Metals, Elgin, Ill). The wire used to
construct the staples is approximately 0.5 mm in diameter
(Fig 4). A deflectable guide sheath is positioned at 90° to
the intended point of fixation. The stapler is then inserted
into the flexible guide and the staple is deployed across the
graft and aortic wall in a two-stage process intended to
engage the full thickness of the vascular wall (Fig 5). The
holding strength of the individual staple is ultimately de-
Fig 3. The Aptus Endograft docking limbs.
Fig 4. The Aptus helical endostaple.pendent on the quality of the tissue into which it is de-
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In a silastic model of a vessel wall, an individual staple
attains a pull-out force of approximately 20 newtons.9 The
helical nature of the staple provides for a low-profile aspect
on vessel penetration when compared to straight barbs or
hooks (Fig 6). Four to six staples are recommended for
fixation with variation in use based on the operator’s dis-
cretion and appreciation of aortic neck morphology and
tissue integrity.
The sequence of steps in the deployment of the graft is
different from currently available endovascular technology.
The initial step in deployment is the exposure of the main
body of the graft once it is in a position near the renal
arteries. This step does not result in proximal stent deploy-
ment. The next step in deployment is release of the proxi-
mal stent in a position determined to be optimal. While this
Fig 5. Fluoroscopic image of staple deployment and transmural
aortic purchase.
Fig 6. The exterior profile of a barb vs a helical staple exiting an
artificial vessel model.is normally at the lowest renal artery, other positions thatwill generate sufficient seal can be chosen in the neck since
fixation is independent of neck length. During the trial,
different proximity to the renal arteries was occasionally
chosen by investigators for anatomic reasons. After proxi-
mal stent release, the main body is still under positive
control of the delivery catheter with nitinol stabilizing bars
attached to the proximal stent and fixation of the ipsilateral
limb to the main delivery catheter. This allows the operator to
support the main body with the delivery catheter until staple
fixation has been achieved. Cannulation of the contralateral
limb is then performed and stapling is performed through
the contralateral limb. After stapling, the contralateral limb
is positioned and deployed. After the contralateral limb is in
place, the main body-tethers to the proximal stent are
released and the ipsilateral docking limb fixation to the
main body delivery catheter is released to allow removal of
the main body delivery catheter. The ipsilateral limb is then
inserted and deployed.
The delivery systems required for the endograft and the
stapling system are significantly smaller than those currently
available. The endograft is delivered via a 5.3-mm (16F)
outer diameter catheter for the 24.5 mm and 26.5 mm
main body diameters and 6.0 mm (18F) for the 29 mm
main body. During this study, 19/21 (90%) were im-
planted with the smaller delivery systems while 2 (10%)
required the 29 mm main body diameter. The stapling
system and endograft limbs also have a 5.3 mm (16F)
crossing profile. The diminished diameter of the catheters
required deploying and stapling the endograft to allow for
both enhanced access in patients with smaller iliac vascula-
ture as well as better control (ie, torque response and
pushability) of the catheter in all vascular morphologies.
METHODS
A prospective, single arm FDA sanctioned phase I IDE
study was performed in six centers. Inclusion criteria in-
cluded a proximal aortic neck length of 12 mm and iliac
landing zone of 10mm. Proximal aortic diameters of 19-26
mm and iliac diameters of 11-14 were required for inclu-
sion. All diameters were measurements of the inner diam-
eter of the aortic or iliac lumen. The primary endpoints
evaluated were safety (major device-related adverse events
at 30 days) and feasibility (successful deployment of all
endograft components). Secondary endpoints included
freedom from endoleaks, rupture, migration, and device
integrity. Inclusion and exclusion criteria are listed in Table I.
Twenty-one patients were enrolled between July 2006 and
May 2007. The primary endpoint of safety was defined by
major adverse events (Table II). The baseline characteristics
and co-morbid conditions of all patients enrolled were
typical of the general population with aortic aneurysm
disease and are listed in Table III. Anatomic evaluation for
satisfaction of inclusion and exclusion criteria was accom-
plished with CT of the abdomen and pelvis with i.v. con-
trast acquired at 3 mm or less intervals. Follow-up evalua-
tion consisted of plain x-rays of the abdomen in four views
and a CT scan at 1 month, 6 months, and annually through
5 years. A core lab (M2S, Lebanon, NH) was utilized for
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and evaluation of each investigator. Aneurysm baseline
diameters were categorized as 45-49 mm through 80-89
mm category with 14 (67 %%) in the 50-59 mm category.
Infrarenal aortic neck length ranged from 13mm to 38mm
with a mean of 26 mm. Baseline anatomic features of the
enrolled patients are listed in Table IV.
RESULTS
Twenty-one patients were treated for AAA with the
Aptus Endovascular AAA Repair System over an 11-month
period.
Technical success. Technical success was achieved in
all 21 patients. All patients have 6-month follow-up and 14
have 12-month evaluations. No mortality, aneurysm rup-
ture, or secondary intervention for aneurysm growth or
endoleak occurred in the subject cohort. There were no
acute or chronic conversions to open surgical procedures.
There were no acute adjunctive open or endovascular pro-
cedures necessary to achieve vascular access (ie, surgical iliac
Table I. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
AAA diameter 5 cm or 4.5 cm
with documented growth of
0.5 cm in the past 6 months
Circumferential thrombus
or significant calcification
in the proximal neck
Non-aneurysmal proximal neck
length of at least 12 mm and
between 19-26 mm in internal
diameter
Ruptured or leaking AAA or
requires emergent AAA
surgery
AAA with an angle of 60°
relative to the long axis of the
aneurysm
Myocardial infarction within
past 10 weeks
Bilateral iliac arteries between
11-14 mm in internal diameter
Requires chronic dialysis or
creatinine 2 times the
laboratory upper limit of
normal
At least 1 cm of non-aneurysmal
tissue in the iliac arteries for
sealing
Active systemic infection
Bilateral femoral/iliac arteries
with an internal diameter
5 mm
Previous AAA repair
Candidate for elective surgical
AAA repair
Planned major procedure
within 30 days of AAA
repair
Life expectancy 2 years Documented hyper-
coagulation condition
AAA, Abdominal aortic aneurysm.
Table II. Major adverse event criteria
Requires therapy/intervention with minor hospitalization 48
hours; or
Major therapy, an unplanned increase in level of care, prolonged
hospitalization (48 hours beyond expected hospital
discharge); or
Permanent adverse sequelae; or
Deathconduit or iliac angioplasty). A total of 96 EndoStapleswere implanted with a range of 2-10 staples per endograft.
The median number of staples in each endograft was four.
EndoStaple implantation was successful in all 96 staple
implantations. Total device time averaged 58 minutes
(range, 32-86) and stapling time averaged 17 minutes
(range, 8-30). A total of four adjunctive prostheses were
used in 3 patients. These included two aortic cuffs, one
balloon-expandable stent used to address inadequate seal-
ing, and one iliac extender for iliac tortuosity and potential
graft kinking. There were no incidences of graft misplace-
ment or migration that required extension or adjunctive
devices. The mean andmedian intensive care unit (ICU) stay
was 0 days and the median hospital stay was 1 day with a
maximum of 10 days. Estimated blood loss intraoperatively
had a median value of 100 cc with a range of 100-900 cc.
Clinical success. No measurable migration proxi-
Table III. Baseline patient characteristics
Characteristic n  21
Age (years)
Mean
Median (min, max) 75 (64-90)
Gender
Male 20 (95%)
Female 1 (5%)
Co-morbid conditions
Coronary artery disease 12 (57%)
Previous MI 5 (24%)
Congestive heart disease 1 (5%)
Valvular heart disease 5 (24%)
COPD 5 (24%)
History smoking 19 (90%)
Hypertension 15 (71%)
Stroke 2 (10%)
Renal failure/insufficiency 3 (14%)
Peripheral arterial disease 2 (10%)
Other significant medical conditions 21 (100%)
MI, Myocardial infarction; COPD, chronic obstructive pulmonary disease.
Table IV. Baseline aorta and aneurysm characteristics
per investigator
Parameter n  21
Neck length (mm)
Mean (min, max) 26.4 (13.0-38.0)
Neck angle (°)
Mean (min, max) 25.3 (9.0-60.0)
Neck diameter (mm) – Aortic-renals
Mean (min, max) 21.4 (15.9-24.0)
Neck diameter (mm) – Aortic-12 mm
Mean (min, max) 22.4 (19.2-28.0)
Aneurysm maximum diameter range
45 mm 0 (0%)
45 mm-49 mm 2 (10%)
50 mm-59 mm 14 (67%)
60 mm-69 mm 3 (14%)
70 mm-79 mm 0 (0%)
80 mm-89 mm 2 (10%)
90 mm 0 (0%)mally, distally, or between graft components has been
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patients experienced three limb thromboses. In one of
these patients, a technical issue related to compression of a
graft limb was deemed responsible. In this patient, the
proximal portion of the iliac limb was not supported by the
radial force of the docking limb and was also in a position of
high angulation resulting in a focal stenosis of the proximal
limb. This patient also had a thrombocytosis and was
evaluated by hematology for this finding. In the second
patient, a diagnosis of hypercoagulability requiring couma-
din therapy was made in addition to a finding of tortuosity
in the iliac vasculature. It is unclear whether or not the
tortuosity of the iliac contributed to the thrombosis as
there was excellent flow with normal ankle-brachial indices
(ABIs) and the patient was able to run vigorously without
claudication following implantation. This patient suffered
an acute occlusion at 3 weeks and a second occlusion of the
contralateral limb occurred 8 months later with no evi-
dence of anatomic obstruction. This patient was diagnosed
as hypercoagulable and coumadin therapy initiated. This
patient also had portal vein thrombosis, as well as two
children on chronic coumadin therapy for multiple throm-
botic events, suggesting a familial disorder of hypercoagu-
lability. Both of these patients were initially diagnosed in
the first 30 days of follow-up. No further limb thromboses
have occurred. As a result of the caliber of the metal in the
staple, the morphology and integrity of each EndoStaple
could also be evaluated throughout follow-up with plain
x-ray. All staples remained in their original location
throughout all follow-up evaluations. There was no change
in any of the 96 staples’ shape or any evidence of fracture
throughout the follow-up period. No stent fracture in
either the main body or iliac limbs was identified (Table V).
Endoleak and aneurysm size. There was no docu-
mentation of type I, III, or IV endoleaks at any follow-up
interval. Type II endoleaks were documented in 4 of 21
(19%) patients at 30 days and 6months, and in 1 of 14 (7%)
patients at 12 months. At 6 months, 9 (42.9%) patients had
a diameter reduction of 5 mm while 19 (90.5%) had a
volume reduction of 5%. Enlargement of 5 mm in diam-
eter was not detected in any patient at 6 months while a
single patient (4.8%) had a greater than 5% volume increase.
The remaining patients were categorized as no change. At
12 months, the 13 patients available for follow-up demon-
Table V. Endoleak evaluation
Event
3- days
follow-up
n  21 n (%)
6-months
follow-up
n  21 n (%)
1-year
follow-up
n  14 n (%)
Endograft leak
Type I 0 (0.0%) 0 (0.0%) 0 (0.0%)
Type II 4 (19%) 4 (19%) 1 (7%)
Type III 0 (0.0%) 0 (0.0%) 0 (0.0%)
Type IV 0 (0.0%) 0 (0.0%) 0 (0.0%)
Indeterminate
origin 0 (0.0%) 0 (0.0%) 0 (0.0%)strated a reduction in aneurysm diameter 5 mm in 9(69.2%) with none enlarging and 4 (30.8%) remaining
stable by diameter criteria. By volume criteria, 11 (84.6%)
had a reduction of 5% while 2 (15.4%) demonstrated an
increase of5%. There have been no secondary procedures
to address endoleak or aneurysm size changes.
Major adverse events. There were a total of 23 major
adverse events cumulatively tabulated over 56 separate
follow-up evaluations (Table VI). There were a total of 3
major adverse events related to the endograft. These three
events occurred in 2 patients and all three were the limb
thromboses detailed earlier in this section. There was no
incidence of graft infection or any new morbidity related to
the aortic aneurysm or the graft.
DISCUSSION
The results of this initial phase I trial validate the safety and
feasibility of an endovascular grafting technique that employs
a separate technique and device for fixation. Despite the
widely-accepted improvements in acute outcomes associated
with endovascular aortic grafting, migration and other en-
dograft integrity failures continue to be a major impediment
to long-term endograft clinical success1,3,7,8,10-13 and more
widespread clinical adoption. The radial force and lack of
effective transmural fixation that characterize most en-
dograft technologies today are largely responsible for the
late complications related to migration and proximal neck
dilatation.4,6,14,15 Irrespective of the design,16,17 any en-
dostapling or independent endovascular fixation technol-
ogy that allows the operator to securely attach a graft or
other device to the load-bearing portion of the vascular
wall, the adventitia, has the potential to change the nature
of endovascular aortic grafting and potentially a variety of
other endovascular procedures and devices. In addition to
the secure attachment of the graft to the wall, the design of
the helical EndoStaples described in this report have the
potential to secure the aortic wall to the graft thus prevent-
ing one of the most insidious late complications of aortic aneu-
rysm repair, namely continued aortic dilation at the proximal
Table VI. Major adverse events
Event category
30 days
N  21
31 to 180 days
n  21
181 to 365 days
n  14
Bleeding 3 0 0
Pulmonary 0 0 0
Cardiac 0 1 1
Renal 0 0 0
Bowel 0 0 0
Wound 1 2 3
Neurologic 0 0 0
Cardiovascular 0 0 0
Aortic & vascular 2** 0 1
Other* 8 2 0
Totals 14 5 4
*Other includes: chest pain, hypotension, urinary tract infection, febrile
episode, decreased Hgb&Hct, tingling/numbness in hand.
**Two patients (three events) with iliac limb occlusion; one related to
underlying hypercoagulable condition.attachment site.4,14,15 The discrete nature of EndoStaples al-
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address of type I endoleaks by creating apposition in an
irregular area not sealed by the uniformity of a radial
stent.18 The independence of an endovascular stapling
device from the primary graft also allows staple application
at a time other than primary graft implantation. This allows
future issues of fixation or other degenerative changes in
the aorta to be addressed with a new endovascular proce-
dure that directly addresses fixation rather than conversion
to open surgery or simple endograft extension.19 While the
benefits of endovascular stapling are well demonstrated in
the application of endograft fixation, there may well be
other applications for independent and discrete fixation in a
variety of vascular pathologies and new treatment para-
digms may be made possible by this new endovascular
modality.
The foundations of successful vascular reconstruction
are based on the development of viable conduits and reli-
able techniques for vascular anastomosis.20,21 While many
endovascular therapies represent alternative methods to
achieve revascularization (ie, endoluminal recanalization vs
bypass), aortic endovascular graft therapy is a reproduction
of open aortic grafting with the exception of endovascular
delivery. The early success of endovascular aortic grafts
satisfied the requirements for reductions in acute morbidity
and mortality relative to the open procedure22,23 but the
inability to reproduce the transmural fixation and control of
the open procedure resulted in long-term outcomes clearly
inferior to open repair.6,13 The potential for endovascular
aortic grafting to surpass both the acute and chronic out-
comes of open reconstruction rests on the development of
technologies that effectively reproduce the principles of
open reconstruction.While the graft materials of both open
and endovascular grafts are similar, the fixation technolo-
gies are radically different. Enabling the surgeon to apply
staples that represent the functional equivalent of a sutured
anastomosis and the control inherent in that technique
holds promise for a significant advance in both the acute
and chronic success of aortic endografting. Such advances
might well allow the endovascular technique to equal and
potentially surpass the chronic performance of open surgi-
cal reconstruction and significantly reduce the current re-
quirements for postoperative imaging. The capability to
deliver a discrete fixation technology independent of the
primary device will allow a new level of creativity in medical
device design for aortic endografts and, potentially, a host
of other devices and therapies.
CONCLUSION
These results document the acute safety and feasibility
of the Aptus Endograft and EndoStaples. Early follow-up
demonstrates excellent 6-month and 1-year results with no
secondary intervention for aneurysm growth or endoleak.
These data are the foundation for a pivotal phase II (STAPLE-2)
trial that is underway at 25 US centers.AUTHOR CONTRIBUTIONS
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Dr Frank Arko (Dallas, Tex). Dr Deaton and coauthors
discuss the early results of the phase I multicenter trial of the Aptus
Endovascular Repair System. I congratulate the authors and the
manufacturers for completing this initial phase. I have several
questions for the authors.
Dr. Deaton, how many EndoStaples are actually necessary for
each case to get a satisfactory outcome? What is the pull-out force
for a staple in tissue as compared to a silicone model?
What is the learning curve on using these EndoStaples? I am
the US principal investigator for a competitive endostapling device
that’s able to be used with any Dacron stent graft and I believe
there is a learning curve to using these devices and I’d like to get
your thoughts on what it is with this device.
Next, please comment on neck calcification, thrombus, angu-
lation, and short neck length on the ability to accurately implant
your EndoStaple and are any of these factors contraindications to
using this endograft?
And then finally, with five currently approved devices within
the United States, all of which have excellent 5-year results, can
you elaborate on what you believe this repair system adds to the
current treatment options?
Dr Deaton. The number of staples required in the phase I
study was 2 but 4 was the number generally recommended and was
the median number in the study. Only 1 patient received 2 staples
and 1 patient had as many as 10. When more than 4 staples were
applied, it was usually to address sealing issues. Fundamentally, the
intention is to give the operator control over how many staples are
needed in their clinical judgment.
While there is undoubtedly a learning curve, the controlled
nature of this helical staple deployment provided for early success
and no misdeployed staples throughout this initial experience. The
positioning of the EndoGuide against the aortic wall followed by
an electronically controlled and staged staple deployment made
the initial learning curve for users fairly shallow.
With respect to the ability of the staple to penetrate aortic
pathology, we don’t have any evidence of staples that did not
penetrate the tissue they were intended to penetrate. That being
said, excessive calcification in the aortic neck is excluded in the trial.
While there is ex vivo evidence of staple penetration through
calcified aortic plaque, we will probably not understand the limi-
tations of this helical staple until we have a much broader experi-
ence in less restricted clinical applications.
With respect to the pullout force, there is early work being
done in a tissue model that I think will back up the numbers
attained in an artificial silastic model. What is fundamentally differ-
ent from most other endograft technologies is that the degree of
fixation achieved by these staples appears to be related to the tissue
into which they are implanted rather than the mechanical integrity
of the staple itself. That is to say that what gives way is the tissue
rather than the structure of the staple. So if it is weak tissue it will
not achieve those high levels of pull-out force just as sutures in
open surgery will tear through tissues with poor integrity. Another
essential aspect of this type of fixation is that it is easily visualized on
postoperative plain x-ray so we will be able to follow any compro-
mise to the staple or any evidence of change in position of a
particular staple.Dr Arko. I think you got most of them. The last one is – and
I’m going to add a little more to it since you made me stand up
here – what do you think the advantages of this endograft is over
other endografts?
And I’d like to ask you if you could describe the actual stent
graft in somemore detail including the distance from the top of the
graft to the flow divider. I have found that with the shorter bodied
stent grafts that it’s actually a bit more difficult to implant the
staples because I lose some ability to guide the catheter and in the
shorter bodied stent grafts I have found it easier to go up both sides
to implant the endostaples. Whereas with a longer bodied stent
graft, I can really get the staples in from either side. Can you
comment on that?
Dr Deaton. With respect to the staple implantation, on rare
occasions we have used both limbs to implant staples, but in over
90% of the cases it is easy to implant staples circumferentially from
one side. The main body in this study was 4 cm long. In the phase
II study, there were 4, 5, and 6 cm body lengths to give the
operator better sizing capabilities and to add flexibility to planning
for unusual anatomic configurations. As for the body length inhib-
iting stapling, we have not seen that. The EndoGuide was specifi-
cally designed to work in the 4 cm length body and the unsup-
ported nature of the main body also allows more flexibility in staple
positioning and deployment.
One of the primary advantages of this endograft system is the
possibility of achieving a degree of proximal fixation on a par with
a hand-sewn anastomosis. If that proves to be the case, wemay well
be able to document a treatment paradigm that does not involve
the lengthy and potentially dangerous necessity of annual CT
scans. Another key advantage of a helical staple is the possibility of
preventing future neck dilatation as the “bidirectional” nature of
helical staple fixation should hold the aorta to the graft rather than
just holding the graft up against the aortic wall. The separation of
the fixation delivery from the graft delivery allows an entirely new
approach to endograft design that maintains a very high degree of
graft structural integrity while bringing the graft delivery catheter
caliber down to 16F. There are a variety of other more nuanced
features made possible by the design of the endograft that we are
still learning about, the most prominent being the non-stented
main body and the ability to treat angulated necks, facilitate
contralateral cannulation, etc. Beyond the scope of this particular
technology, I think any independent fixation technology will allow
an entirely new approach to endograft design that will give the
operator the ability to treat a broader group of patients more
effectively with better long-term results.
Dr Wayne Zhang (Loma Linda, Calif). You use staples for
proximal fixation. Do you have any migration after deployment of
the stent graft before you put staples?
The second question is are you worried about bleeding? Can
the staples cause penetration and bleeding? Do you need to do a
CT scan immediately after the procedure?
And another question is, when you deploy the staples, if you
have an angled neck, how do you position?
Dr Deaton. We don’t see any bleeding from implanting the
staples. We haven’t seen it in an animal model. And it really is the
helical nature of it is much less than what you would do in open
surgery.
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straight across that proximal stent, because that is where we like to
implant the staples.
And your first question again was?
Dr Zhang. Do you have any migration after deployment of
the stent graft before you put staples?
Dr Deaton. Can you move the graft? It can move, but that
proximal sealing stent has a fairly high radial force so it’s done with
some difficulty. But before you do that, when you uncover the
entire graft, it’s easily mobile at that point.
DrWesleyMoore (Los Angeles, Calif). Does the device go up
bare or are you putting it in through a sheath?
How far beyond the outer wall of the aorta does the staple go?
Do you have any concern about puncturing the left renal vein or
the cava when you put the staple in place?
Dr Deaton. As far as the staple penetration, it’s 4 mm and it’s
designed to basically just go through the aortic wall. We’ve not
seen any complications related to it. And I’ve neglected to show
you a slide, but it’s very different, when you penetrate a vessel with
a barb, you have a barb sticking through the aorta. This helical
screw has a much lower profile. It doesn’t have something sticking
up like a nail, if you will.
Dr Moore. Does this go bare or through a sheath?
Dr Deaton. It’s designed to go bareback and it can. If they
have adequate iliac access vessels, we do place a sheath just to
facilitate exchanges and intraoperative imaging but there is no
reason you have to place a sheath. The delivery system, as you can
see, is tapered and we generally re-jacket the entire delivery system
on removing it to prevent any iliac trauma.
DrMoore. Finally, in one of the patients you mentioned that
you placed one or two cuffs proximally. Was that because the graft
moved before you had a chance to staple it, or did you staple it and
had to place cuffs in addition to that?
Dr Deaton. It wasn’t because the graft moved, but I think it
was because of some irregularity in the neck that the short stentdidn’t fulfill the sealing requirements and so we added support to
the main body to lengthen the sealing zone. In the phase II study,
which is underway now, an aortic cuff designed specifically for this
unique endograft system has been added to the portfolio of the
system. This allows operators the ability to provide for a longer
sealing zone in the main body with the fully-stented aortic cuff
positioned within the main body or to extend the length of the
main body cephalad when a more distal area is deemed more
appropriate for staple implantation.
Dr Jean Panneton (Norfolk, Va). As a co-investigator in the
Aptus trial, I can tell you all that it’s actually a very slick device. I
think the delivery is very intuitive which, as surgeons, we like. I
think the learning curve for the EndoStapler is actually pretty
short. I think it’s also very intuitive to use and very user friendly.
One potential improvement would be shortening the radius of
the EndoStapler, especially when there is angulation of the aneu-
rysm neck; I think it would help the stapling.
My concern is the limb occlusion rate. I’m sure you have that
same concern. I think you might explain this as technical difficul-
ties or maybe from the iliac anatomy, but do you think there is a
need to change the graft to try to prevent this problem? Is it
because it is so flexible and does not have columnar strength that
it’s going to be more likely to kink or occlude in tortuous iliacs?
Dr Deaton. We’ve had 2 patients with limb occlusions and 1
of those was diagnosed with a severe hypercoagulability condition
postoperatively. The other patient with a limb occlusion was likely
the result of deploying the limb too low in the docking zone
resulting in an unsupported proximal limb that happened to be at
an angulated portion of the aorta where the neck terminated into
the aneurysm sac. Having said that, there have been several design
changes in the endograft system being used in the phase II to
provide for better adaptation to tortuosity such that even acute
bends of 90° can be accommodated by the graft limbs without
luminal compromise.
